Director, Preclinical Strategy,
Mike Bravo is the Director of Preclinical Strategy for NAMSA, the world's first and only Medical Research Organizationâ€”which uses a global approach in combining lab testing, preclinical, regulatory, biostatistical, clinical, and quality system services to solve problems, shorten timelines, build value, and reduce risk to clients. Mike's role is to assist clients in developing preclinical strategies for testing from proof-of-concept through GLP as well as marketing and physician training studies. Mike also works cross-functionally with colleagues in regulatory, biostatistics, and clinical to add value to clients' development plans. In addition, he performs a large number of surgical and interventional procedures for clients. He has authored several publications and posters, with a focus on model development. With 20 years of experience in preclinical research and medical device development, Mike's background includes experience in academia, industry, and contract research labs. He earned his Surgical Research Specialist (SRS) certification from the Academy of Surgical Research and is a member of the Society of Interventional Radiology (SIR).